FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring

In this segment, the panel digs into the new data from the FLORA-2 trial being presented at this year's World Conference on Lung Cancer, covering both a biomarker analysis examining TP53 co-mutation and acquired resistance mechanisms and an extended safety follow-up. You will hear what the biomarker data tell us about who benefits from combination therapy and whether the presence or absence of TP53 changes your approach. The panel also addresses what a longer view of safety reveals that the primary analysis could not, with particular attention to renal toxicities emerging on maintenance. The discussion then shifts to how serial ctDNA monitoring is being used in practice to guide decisions about intensification, including what a failure to clear ctDNA means for a patient started on monotherapy.